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Supplemental Figure legends 
Supplemental Fig. 1. A, Proteins features that interact with AR. Extract from PC3wtAR cells was passed 
through an AR conjugated immuno-column to isolate AR specific interacting proteins. The bound 
proteins were then eluted for separation on a 2-dimensional gel electrophoresis (2-DE)  followed by silver 
staining. Selected protein features were excised using a sterile 200μl pipette tip and placed in a PCR tube 
with 5μl of HPLC grade water and sequenced by mass spectrometry. The spot identified as p23 is circled 
in red. B & C, Protein levels in GST pulldown assays in Figures 1B and 5A. GST- alone or GST- fused to 
full length p23 or truncated domains was expressed in E.Coli BL21 strain by Isopropyl-β-D-
thiogalactopyranoside (IPTG) induction using the pGEX-6P1 vector system. Induced GST fused protein 
was then purified from the culture using glutathione affinity sepharose beads. Comparable amounts of 
GST control or GST-p23 was then used (as shown in the Coomasie blue-stained SDS-PAGE) for the 
pulldown assay. 
 
 Supplemental Fig. 2. Protein expression levels for cells used in reporter assay (Figure 2A and B) Western 
blot shows expression levels of AR. 5 μg of total protein was extracted from A, PC3wtAR and B, MCF7 
cells following transient transfection with pSG5-p23 for subsequent separation by SDS-PAGE. The 
Western blot was probed using antibodies specific for AR, p23 and β-actin. Figures are representative 
blots. 
 
Supplemental Fig. 3. p23 protein expression levels in response to DOX and knockdown treatments. A, 
LNCaP-TR2-p23 cells (stably transfected with a doxycycline-inducible plasmid expressing V5 tagged 
p23) were cultured in media containing 100 nM DOX for 48 h prior to starvation for 72 h in the presence 
of 100 mM DOX. Cells were then treated ± 10 nM MB for 6, 10 or 16 h and harvested. 5 μg of protein 
was resolved and probed with antibodies against V5 and β-actin. B, LNCaP cells were transiently 
transfected with siRNA pool against p23 or scrambled negative control. 48 h later, cells were treated ± 10 
nM MB ± 10 nM 17-AAG for 24 h before harvesting and probing 5 µg extract with antibodies against 
p23 and β-actin. 
 
Supplemental Fig. 4. Subcellular localization of p23 and AR. A, PC3wtAR cells were grown on glass 
coverslips to 70% confluency. Cells were starved for 48 h prior to treatment with 10 nM MB or vehicle 
control for 2 h. Cells were washed with PBS before fixing in 4% paraformaldehyde (PFA) for 15 min  
followed by immunostaining for p23 and AR using Alexa-488 or Alexa-596 secondary antibody 
respectively for visualization by confocal microscopy. B, Chromatin immunoprecipitation was performed 
on LNCaP cell extracts incubated with 10 nM MB for 2 h. IP was performed using an antibody specific 
for p23 or control IgG and RT-qPCR performed on the immunoprecipitated DNA to detect the presence 
of one non-ARE  (Negative region) and two specific ARE sequences (Enhancer and Promoter) of the AR 
target gene, KLK2. 
 
Supplemental Fig. 5. The effect of HSP90 inhibitors on cell viability as well as AR and p23 expression 
levels. . A, LNCaP cells were treated with vehicle (DMSO) or 5 µM 17-AAG for the specified time 
points. Cell viability was determined by using the MTT viability assay with absorbance readings at 570 
nm. B, PC3wtAR cells were treated with ± 10 nM MB, ± geldanamycin (GA) at the indicated 
concentrations, for 2 h. Immunoprecipitation was performed using anti-p23 antibody and the precipitated 
complex resolved and probed using antibodies against p23, HSP90 and AR. C, MCF7 cells were grown 
for 24 h in full media prior to being incubated in starvation media for 24 h. 1, 10 and 100 nM of GA in 
combination with 10 nM MB was added to the cells for a further 16 h. Cell toxicity was determined by 
using the sulforhodamine B (SRB) assay with absorbance readings at 495 nm. Gray bars: time = 0 hours, 
black bars: time = 16 hours.
Supplemental Table 1. RT-qPCR primers used in this study. 
qRT-PCR primer name  Sequence or Applied bioscience reference code  
p23  HS00832847_9H 
GAPDH  HS99999905_A1 
PSA  HS00426383_A1  
KLK2  HS00377590_S1  
PSA (Forward) 5’-TTGTCTTCCTCACCCTGTCC- 3’  
PSA (Reverse) 5’-AGCTGTGGCTGACCTGAAAT- 3’  
KLK2 (Forward) 5’-CCTCACGTTCTGGCATCACTT- 3’  
KLK2 (Reverse) 5’-CGGCCAGGTGAGTTCCAA- 3’  
DRG1 (Forward) 5’-GCAGCACACACTTCACAAAGC- 3’  
DRG1 (Reverse) 5’-CCAGGCACCCGTTTGAAC- 3’  
TMPRSS 2 (Forward) 5’-AATCGGTGTGTTCGCCTCTAC- 3’  
TMPRSS 2 (Reverse) 5’-AATCGGTGTGTTCGCCTCTAC- 3’  
L19 (Forward) 5’-GCGGAAGGGTACAGCCAAT- 3’  
L19 (Reverse) 5’-GCAGCCGGCGCAAA- 3’  
PSA-negative region (Forward)  5’-TCCACTCCAGCTCTAAGATGGT- 3’  
PSA-negative region (Reverse)  5’-CAGGTAAACTCCAAGCACAGTGA- 3’  
PSA-Promoter-ARE (Forward)  5’-GTGCATCCAGGGTGATCTAGTAATT- 3’  
PSA – Promoter-ARE (Reverse)  5’-CACACCCAGAGCTGTGGAA- 3’  
PSA – Enhancer-ARE (Forward) 5’-TGACAGTAAACAAATCTGTTGTAAGAGACA- 3’  
PSA – Enhancer-ARE (Reverse) 5’-AGCAGGCATCCTTGCAAGAT- 3’  
KLK2 – Negative region (Forward) 5’-TGGGTGATGTGGTTGGATTGG- 3’  
KLK2 – Negative region (Reverse) 5’-CCCATGATAACCTCAACCAAAACCT- 3’  
KLK2 – Promoter-ARE (Forward) 5’-GCCTCCAGACTGATCTAGTATGTGT- 3’  
KLK2 – Promoter-ARE (Reverse) 5’-CACACCCAGAGCTGTGGAA- 3’  
KLK2 – Enhancer-ARE (Forward) 5’-TTTATAATTGGGTTGAAAGCAGACCTAC-3’  
KLK2 – Enhancer-ARE (Reverse) 
TMPRSS2 – Enhancer ARE (Forward) 
TMPRSS2 – Enhancer ARE (Reverse) 
5’-AGCAGATTTGTTTACTGTTCAGGACA-3’  
5’-TCCCAAATCCTGACCCCA-3’ 
5’-ACCACACAGCCCCTAGGAGA 
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